Silychristin: Skeletal Alterations and Biological Activities
David Biedermann1, Martin Buchta2, Veronika Holečková1
1Institute of Microbiology, Laboratory of Biotransformation, Czech Academy of Sciences , Vídeňská 1083, CZ 142 20 Prague, Czech Republic.
Journal of Natural Products
|December 24, 2016
Summary
Silychristin and its derivatives from Silybum marianum are potent antioxidants, surpassing silybin in radical scavenging and lipoperoxidation inhibition. These compounds show low cytotoxicity, suggesting they drive silymarin
Area of Science:
- Natural Product Chemistry
- Pharmacology
- Medicinal Plant Research
Background:
- Silychristin is a major flavonolignan in Silybum marianum fruits.
- Silymarin, a complex of flavonolignans, is known for its therapeutic properties.
- Silybin is the most abundant flavonolignan, but silychristin's role is also significant.
Purpose of the Study:
- To investigate the antioxidant and cytotoxic properties of silychristin and its derivatives.
- To compare the antioxidant potential of silychristin analogues with silybin.
- To elucidate the contribution of silychristin to the overall antioxidant activity of silymarin.
Main Methods:
- High-resolution physicochemical data acquisition.
- Optimization of 2,3-dehydrosilychristin preparation.
- In vitro antioxidant assays: Folin-Ciocalteau reduction, DPPH, and ABTS radical scavenging.
- Microsomal lipoperoxidation inhibition assay.
- Cytotoxicity assessment across 10 human cell lines.
Main Results:
- Silychristin and its analogues demonstrated potent antioxidant activity, exceeding that of silybin.
- Compounds 4-6 effectively inhibited microsomal lipoperoxidation with IC50 values of 4-6 μM.
- Compounds 4-8 exhibited negligible cytotoxicity against various human cell lines.
- The absolute configuration of silyhermin was proposed, matching silychristin A.
Conclusions:
- Silychristin and its derivatives are powerful antioxidants with significant potential.
- These compounds are likely the primary drivers of silymarin's antioxidant effects, rather than solely silybin.
- The low cytotoxicity and high antioxidant capacity suggest therapeutic applications for silychristin analogues.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
289
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
289
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K

